PMV Pharmaceuticals (PMVP) Non-Current Assets (2019 - 2026)
PMV Pharmaceuticals' (PMVP) quarterly Non-Current Assets came in at $782000.0 in Q1 2026, down 89.0% YoY from $7.1 million in Q1 2025, and down 41.42% on a QoQ basis from $1.3 million in Q4 2025.
PMV Pharmaceuticals (PMVP) Non-Current Assets (2019 - 2026) Analysis & Trends
PMV Pharmaceuticals (PMVP) has 8 years of Non-Current Assets data on file, last reported at $782000.0 in Q1 2026.
- Quarterly Non-Current Assets fell 89.0% year-over-year to $782000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.1 million (down 85.33% YoY) and the FY2025 annual result came in at $1.3 million, down 91.46% from the prior year.
- Non-Current Assets declined to $782000.0 in Q1 2026, from $1.3 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $55.7 million in Q3 2023 to a low of $782000.0 in Q1 2026.
- A 5-year average of $22.5 million and a median of $19.8 million in 2022 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2023 — Non-Current Assets jumped 181.36% — and 2025, when it slumped 95.88%.
- Tracing PMVP's Non-Current Assets over 5 years: stood at $23.3 million in 2022, then jumped by 92.01% to $44.7 million in 2023, then slumped by 65.07% to $15.6 million in 2024, then slumped by 91.46% to $1.3 million in 2025, then sank by 41.42% to $782000.0 in 2026.
- The last three Non-Current Assets figures came in at $782000.0 (Q1 2026), $1.3 million (Q4 2025), and $1.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | PMV Pharmaceuticals | 70.74 Mn | -8.69 Mn | - | 659,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 782,000.00 |
| Dec 31, 2025 | 1.34 Mn |
| Sep 30, 2025 | 1.40 Mn |
| Jun 30, 2025 | 7.54 Mn |
| Mar 31, 2025 | 7.11 Mn |
| Dec 31, 2024 | 15.63 Mn |
| Sep 30, 2024 | 33.88 Mn |
| Jun 30, 2024 | 18.75 Mn |
| Mar 31, 2024 | 34.42 Mn |
| Dec 31, 2023 | 44.74 Mn |
| Sep 30, 2023 | 55.73 Mn |
| Jun 30, 2023 | 51.80 Mn |
| Mar 31, 2023 | 20.68 Mn |
| Dec 31, 2022 | 23.30 Mn |
| Sep 30, 2022 | 19.81 Mn |
| Jun 30, 2022 | 18.70 Mn |
| Mar 31, 2022 | 26.97 Mn |
| Dec 31, 2021 | 30.28 Mn |
| Sep 30, 2021 | 30.62 Mn |
| Jun 30, 2021 | 32.83 Mn |